23:24 , Nov 7, 2018 |  BC Extra  |  Company News

Management tracks: Myovant, Alkahest

Women’s health and endocrine disease company Myovant Sciences Ltd. (NYSE:MYOV) named Kim Sablich chief commercial officer and Jeff Nornhold SVP of pharmaceutical operations and development. Sablich was VP of primary care marketing in the U.S....
02:27 , Nov 3, 2018 |  BioCentury  |  Product Development

New partners for NASH

Pharmas are loading up their NASH portfolios expecting that addressing the full disease spectrum will require combinations, though the field lacks the tools to sort the different mechanisms on offer strategically. Meanwhile, at least three...
19:58 , Nov 2, 2018 |  BC Week In Review  |  Company News

Linzess growth figures disappoint investors

Allergan plc (NYSE:AGN) said it expects future growth for Linzess linaclotide to be in the low- to mid-single digits, sending shares of partner Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) down $2.91 (18%) to $13.18 on Oct. 30....
19:53 , Nov 2, 2018 |  BC Week In Review  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
20:40 , Nov 1, 2018 |  BioCentury  |  Finance

OrbiMed’s NASH Terns

Terns Pharmaceuticals Inc. brings a dual U.S.-China strategy and a diverse pipeline to OrbiMed’s non-alcoholic steatohepatitis investment portfolio. OrbiMed co-led the biotech’s $80 million series B on Oct. 30 with fellow new investor Vivo Capital....
21:57 , Oct 30, 2018 |  BC Extra  |  Company News

Linzess growth figures disappoint investors

Allergan plc (NYSE:AGN) said it expects future growth for Linzess linaclotide to be in the low- to mid-single digits, sending shares of partner Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) down $2.91 (18%) to $13.18. Allergan, which relayed...
20:30 , Oct 29, 2018 |  BC Extra  |  Company News

Pfizer, Novartis in NASH deal with multiple MOAs

Pfizer Inc. (NYSE:PFE) and Novartis AG (NYSE:NVS; SIX:NOVN) partnered to test Novartis' tropifexor (LJN452) in combination with three compounds from Pfizer with different mechanisms of action to treat non-alcoholic steatohepatitis. The partners will conduct preclinical...
22:43 , Oct 26, 2018 |  BioCentury  |  Finance

Earnings on deck

Earnings on deck...
17:03 , Oct 26, 2018 |  BC Week In Review  |  Financial News

Antibiotics play Qpex launches with Medicines Co. assets, BARDA deal

With $33 million in new series A funding, a portfolio of preclinical assets from The Medicines Co. (NASDAQ:MDCO) and a BARDA deal, Qpex Biopharma Inc. (San Diego, Calif.) hopes to begin clinical studies of multiple...
15:56 , Oct 26, 2018 |  BioCentury  |  Finance

Rempex remix

New Enterprise Associates led Qpex Biopharma Inc.’s $33 million A round in hope that the management team will repeat its performance at Rempex Pharmaceuticals Inc. and The Medicines Co. (NASDAQ:MDCO) with a preclinical anti-infectives portfolio....